Belite Bio (BLTE) vs Dianthus Therapeutics (DNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Belite Bio (BLTE) over the past year, gaining 104.0% versus a gain of 5.7%. Belite Bio is the larger company by market cap ($5.17 billion vs $4.76 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | DNTH |
|---|---|---|
| Share price | $127.38 | $84.55 |
| Market cap | $5.17B | $4.76B |
| 1-day change | -15.65% | -0.33% |
| YTD return | -20.37% | +105.17% |
| 1-year return | +5.66% | +103.98% |
| 5-year return | — | -12.80% |
| EPS (TTM) | $-2.84 | $-4.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.04M |
| Revenue growth (YoY) | — | -67.35% |
| Net income (latest FY) | $-77.61M | $-162.34M |
| Operating margin | — | -8739.34% |
| Net margin | — | -7973.33% |
| 52-week high | $200.00 | $117.88 |
| 52-week low | $115.41 | $35.84 |
| Distance from 52-week high | -36.31% | -28.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +82.92% | +64.70% |
| Average volume | 195.65K | 848.96K |
| Shares outstanding | 40.61M | 56.31M |
| Employees | 41 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed BLTE by 98.3 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
BLTE vs DNTH FAQ
Which is bigger, Belite Bio or Dianthus Therapeutics?
Belite Bio (BLTE) is larger, with a market capitalization of $5.17B compared with $4.76B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, BLTE or DNTH?
DNTH returned +103.98% over the past 12 months, compared with +5.66% for BLTE (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Dianthus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.